NCT04546620 2025-08-06
REMoDL-A
University Hospital Southampton NHS Foundation Trust
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT03995147 2025-06-08
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
University of Chicago
Phase 2 Active not recruiting
NCT04566887 2025-02-18
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
University Health Network, Toronto
Phase 2 Recruiting
NCT06647940 2024-10-22
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）
Sun Yat-sen University
Phase 2 Recruiting
NCT02633137 2024-08-30
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00268853 2024-05-30
RAPID
CTI BioPharma
Phase 2 Completed
NCT04263584 2024-01-05
COPA-R-CHOP
University Hospital Muenster
Phase 2 Unknown
NCT02660710 2022-10-28
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02605694 2021-03-17
Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
SecuraBio
Phase 2 Withdrawn
NCT02890602 2020-02-20
Erythropoietin for Management of Anemia Caused by Chemotherapy
Kosin University Gospel Hospital
Phase 2 Completed
NCT02792491 2016-06-09
Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over
Pusan National University Hospital
Phase 2 Unknown
NCT00946374 2009-07-27
HD-MCL2003
Heidelberg University
Phase 2 Unknown